Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
Titel:
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
Auteur:
Hiwase, Devendra Tan, Peter D’Rozario, James Taper, John Powell, Anthony Irving, Ian Wright, Matthew Branford, Susan Yeung, David T. Anderson, Luke Gervasio, Othon Levetan, Carly Roberts, Will Solterbeck, Ann Traficante, Robert Hughes, Timothy